Receptor Activity-modifying Proteins 2 and 3 Generate Adrenomedullin Receptor Subtypes with Distinct Molecular Properties.

Paul W R Harris, Debbie L Hay, Christopher A Reynolds, Augen A Pioszak, Alex C Conner, Michael J Woolley, David R Poyner, James Barwell, Margaret A Brimble, Tsz-Ying Yuen, Harriet A Watkins, Arran Constantine, Alex Lathbridge, James M W R McElhinney, Meenakshi Pardamwar, Michael Garelja, Joseph J Gingell, Rekhati S Abhayawardana, Madhuri Chakravarthy

Journal: The Journal of biological chemistry 2016;291(22):11657-75

PMID: 27013657

Abstract

Adrenomedullin (AM) is a peptide hormone with numerous effects in the vascular systems. AM signals through the AM1 and AM2 receptors formed by the obligate heterodimerization of a G protein-coupled receptor, the calcitonin receptor-like receptor (CLR), and receptor activity-modifying proteins 2 and 3 (RAMP2 and RAMP3), respectively. These different CLR-RAMP interactions yield discrete receptor pharmacology and physiological effects. The effective design of therapeutics that target the individual AM receptors is dependent on understanding the molecular details of the effects of RAMPs on CLR. To understand the role of RAMP2 and -3 on the activation and conformation of the CLR subunit of AM receptors, we mutated 68 individual amino acids in the juxtamembrane region of CLR, a key region for activation of AM receptors, and determined the effects on cAMP signaling. Sixteen CLR mutations had differential effects between the AM1 and AM2 receptors. Accompanying this, independent molecular modeling of the full-length AM-bound AM1 and AM2 receptors predicted differences in the binding pocket and differences in the electrostatic potential of the two AM receptors. Druggability analysis indicated unique features that could be used to develop selective small molecule ligands for each receptor. The interaction of RAMP2 or RAMP3 with CLR induces conformational variation in the juxtamembrane region, yielding distinct binding pockets, probably via an allosteric mechanism. These subtype-specific differences have implications for the design of therapeutics aimed at specific AM receptors and for understanding the mechanisms by which accessory proteins affect G protein-coupled receptor function.

© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Address: From the School of Biological Sciences, the Maurice Wilkins Centre for Molecular Biodiscovery, and.; From the School of Biological Sciences.; the School of Biological Sciences, University of Essex, Wivenhoe Park, Colchester CO4 3SQ, United Kingdom.; the Maurice Wilkins Centre for Molecular Biodiscovery, and the School of Chemical Sciences, University of Auckland, Auckland 1010, New Zealand.; the School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, United Kingdom.; the School of Clinical and Experimental Medicine, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.; the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104.; the School of Biological Sciences, University of Essex, Wivenhoe Park, Colchester CO4 3SQ, United Kingdom, [email protected].; From the School of Biological Sciences, the Maurice Wilkins Centre for Molecular Biodiscovery, and [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.